Sugi Predict

Sugi Predict / Compounds / SCHEMBL2116718

SCHEMBL2116718

SCHEMBL2116718

OCc1cccc2c(Br)cccc12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 1/20 0.41
▸ PRNP P04156 1/20 0.40
▸ KDM4E B2RXH2 2/20 0.38
▸ LMNA P02545 2/20 0.38
▸ TP53 P04637 1/20 0.38
▸ MAPT P10636 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ ALOX12 P18054 1/20 0.38
▸ APOBEC3G Q9HC16 1/20 0.38
▸ MEN1 O00255 3/20 0.38
▸ KMT2A Q03164 3/20 0.38
▸ PLAU P00749 1/20 0.38
▸ TAAR1 Q96RJ0 1/20 0.37
▸ PDCD1 Q15116 1/20 0.36
▸ CD274 Q9NZQ7 1/20 0.36
▸ GABRA1 P14867 1/20 0.36
▸ GABRB2 P47870 1/20 0.36
▸ IDO1 P14902 2/20 0.35
▸ AHR P35869 1/20 0.35
▸ CYP2A6 P11509 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5752787 0.86 RXFP1 (0.41) PRNPKDM4ELMNAMAPTAPOBEC3G
SCHEMBL31281348 0.86 RXFP1 (0.41) PRNPKDM4ELMNAMAPTAPOBEC3G
SCHEMBL16415013 0.85 TAAR1 (0.38) PARP1PRNPMEN1KMT2APLAU
SCHEMBL29602462 0.84 APOBEC3G (0.48) KDM4ELMNATP53MAPTTSHR
SCHEMBL3034972 0.84 APOBEC3G (0.48) KDM4ELMNATP53MAPTTSHR
SCHEMBL15351615 0.81 POLB (0.37) PARP1PRNPKDM4EMEN1KMT2A
SCHEMBL9313596 0.81 PARP1 (0.41) PARP1PRNPLMNATSHRMEN1
SCHEMBL6387817 0.81 PARP1 (0.41) PARP1PRNPTSHRMEN1KMT2A
SCHEMBL16415144 0.80 MCL1 (0.36) PARP1PRNPKDM4EMAPTTSHR
SCHEMBL11893015 0.79 GABRA1 (0.56) PARP1PRNPLMNATSHRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11891369-B2 Compounds for binding proprotein convertase subtilisin/kexin type 9 SRX CARDIO, LLC (US) 2024-02-06 — — US disclosed
EP-4209492-A1 COMPOUND FOR TREATING THROMBOTIC DISEASES Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2023-07-12 — — EP disclosed
US-20210032214-A1 COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 SRX CARDIO, LLC 2021-02-04 — — US disclosed
US-20210032214-A1 COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 SRX CARDIO, LLC 2021-02-04 — — US disclosed
US-20190119236-A1 COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) SRX CARDIO, LLC 2019-04-25 — — US disclosed
US-20190119236-A1 COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) SRX CARDIO, LLC 2019-04-25 — — US disclosed
EP-2872490-B1 ANTIPROLIFERATIVE BENZO[B]AZEPIN-2-ONES HOFFMANN LA ROCHE (CH) 2018-02-07 — — EP disclosed
WO-2017147328-A1 COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PORTOLA PHARMACEUTICALS, INC. (US) 2017-08-31 — — WO disclosed
WO-2017147328-A1 COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PORTOLA PHARMACEUTICALS, INC. (US) 2017-08-31 — — WO disclosed
US-20170197968-A1 Compositions and Methods for Inhibiting BMP NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-07-13 — — US disclosed
US-20060183790-A1 Azolylacylguanidines as beta-secretase inhibitors WYETH (US) 2006-08-17 — — US disclosed
US-20060183790-A1 Azolylacylguanidines as beta-secretase inhibitors WYETH (US) 2006-08-17 — — US disclosed
US-20060183790-A1 Azolylacylguanidines as beta-secretase inhibitors WYETH (US) 2006-08-17 — — US disclosed
EP-1577305-A1 Oral antidiabetic agents WARNER-LAMBERT COMPANY LLC (US) 2005-09-21 — — EP disclosed
CN-1558897-A oral antidiabetic agent ����-�����ع�˾ 2004-12-29 — — CN disclosed
EP-1423363-A1 ORAL ANTIDIABETIC AGENTS Warner-Lambert Company LLC (US) 2004-06-02 — — EP disclosed
US-20030171377-A1 Antidiabetic agents BIGGE CHRISTOPHER FRANKLIN (US) 2003-09-11 — — US disclosed
WO-2003018553-A1 ORAL ANTIDIABETIC AGENTS WARNER-LAMBERT COMPANY LLC (US) 2003-03-06 — — WO disclosed
US-5350752-A Dihydropyrimidine derivatives E. R. SQUIBB & SONS, INC. (US) 1994-09-27 — — US disclosed
EP-0547442-A1 Dihydropyrimidin derivatives used as A-II receptor antagonists E.R. SQUIBB & SONS, INC. (US) 1993-06-23 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11891369-B2 Compounds for binding proprotein convertase subtilisin/kexin type 9 PCSK9, PCSK6, PCSK7 PARP1 876/4885PRNP 1316/4885KDM4E 2393/4885
US-20030171377-A1 Antidiabetic agents SLC5A1, SLC5A2, GLP1R PARP1 3703/4885PRNP 4793/4885KDM4E 1064/4885
US-20060183790-A1 Azolylacylguanidines as beta-secretase inhibitors BACE1, BACE2, APP PARP1 2311/4885PRNP 342/4885KDM4E 1462/4885
US-20210032214-A1 COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 PCSK9, PCSK6, PCSK7 PARP1 571/4885PRNP 1816/4885KDM4E 2046/4885
US-20170197968-A1 Compositions and Methods for Inhibiting BMP BMP1, BMP2, BMPR2 PARP1 4641/4885PRNP 4379/4885KDM4E 3505/4885
US-20190119236-A1 COMPOUNDS FOR BINDING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) PCSK9, PCSK6, PCSK7 PARP1 726/4885PRNP 2225/4885KDM4E 2446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.